Feed/Companies/Samplix

Samplix

As of 1 Nov 2026, Samplix has raised $27.8M across 1 verified round on record (amounts in other currencies converted to USD); latest: €25M first close round led by WLanholding GmbH (“WLan”), announced 27 Oct 2026.

BUILT ON

Visit site

Samplix provides advanced single cell analysis and isolation technology to reveal cell function at single-cell resolution.

samplix.comLinkedInCopenhagen, DenmarkBiotechFounded 2013

LATEST ROUND

First close

$27.8M · 2026-10-27

RAISED ON RECORD · USD

$27.8M

across 1 verified round

INVESTORS

1 lead

SOURCES

from 3 publishers

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Rounds

[ 1 ]

First close

$27.8M · 2026-10-27

led by WLanholding GmbH (“WLan”)

Round	Amount	Announced	Lead	Buzz
First close	$27.8M €25M	2026-10-27	WLanholding GmbH (“WLan”)	No recent discussion
3 sources · checked 4 times, last 1h ago [ VERIFIED ] read against 3 sources Source 2 displays October 26 above the release, but its dateline and Source 1 identify October 27; the dateline controls. €30 million is only a target, not a financing total.; not on the page it cites, so not applied: headquarters

Company research

Fetched 3d ago

Founders

Thomas Kvist · co-founder
Michael Obermayer · Chairman & Co-Founder
He previously held roles at McKinsey & Co. and Fjord Capital Partners.

WHY IT MATTERS

Samplix is tackling the limits of bulk and marker-only assays by putting living cells or DNA into uniform double-emulsion droplets that work with standard flow cytometers and sorters, enabling function-first single-cell screening and antibody discovery. Its October 2026 financing first close of €25 million, led by WLanholding and comprising €3 million of new capital plus €22 million of shareholder convertible-bond conversions, is intended to expand commercial adoption of Xdrop in antibody discovery and biotherapeutic development.

Checked against 8 sources 3d ago

SOURCES

eu-startups.com/2026/10/danish-biotech-samplix-secures-e25-million-in-first-close-of-financing-round-to-scale-antibody-discovery

Samplix

Company

Rounds

Sources

Profile

Investors

Samplix

Rounds

Company research

Sources

First close$27.8M2026-10-273 sources

Profile

Investors

First close$27.8M2026-10-271 investor